Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05062863 · ClinicalTrials.gov registry record
An Observational Clinical Study of the T3 Dental Implant System
A clinical trial of Edentulous Jaw, sponsored by ZimVie.
- Active
- Registry status
- 140
- Enrollment target
- 4
- Study locations
NCT05062863: Active study of Edentulous Jaw, sponsored by ZimVie.
NCT05062863 is a study of Edentulous Jaw that is active but no longer recruiting, run by ZimVie. The registered enrollment target is 140 participants. The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05062863, a study of Edentulous Jaw, is active but no longer recruiting, sponsored by ZimVie.
- ACTIVE NOT RECRUITING
- Registry status
- 140 participants
- Enrollment target
- 4
- Study locations
Study Summary
This will be a prospective, observational study where all implants will be placed in either the maxilla or mandible and loaded immediately (within 48 hours), early (within 6-8 weeks) or delayed (\> 8 weeks) with a provisional or definitive prosthesis. The implants will be evaluated yearly for 2 years.
Primary Outcome
The integration success measured by lack of mobility
Conditions Studied
Interventions
- DEVICE T3 dental implant system
Study Locations (4)
Florida
- University of Florida - Gainesville
New Jersey
- Jersey Shore University Medical Center - Neptune City
Virginia
- Virginia Commonwealth University - Richmond
Other
- Dr. Daniel Engler-Hamm - München
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2021-10-20 |
| Est. Completion | 2026-08 |
What the registry record for NCT05062863 still lists
NCT05062863 is an observational study that tracks outcomes without assigning an intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Edentulous Jaw appearing as the primary indexed condition, and to 1 intervention - of which T3 dental implant system is the first listed.
NCT05062863 reports a single indexed study location in Florida, New Jersey, Virginia.
Frequently Asked Questions
What is clinical trial NCT05062863 about?
NCT05062863 is a clinical study titled "An Observational Clinical Study of the T3 Dental Implant System". This will be a prospective, observational study where all implants will be placed in either the maxilla or mandible and loaded immediately (within 48 hours), early (within 6-8 weeks) or delayed (\> 8 weeks) with a provisional or definitive prosthesis. The implants will be evaluated yearly for 2 year...
What is the current status of trial NCT05062863?
This trial is currently active not recruiting. The enrollment target is 140 participants. The study started on 2021-10-20. Estimated completion is 2026-08.
What conditions does trial NCT05062863 study?
This clinical trial studies the following conditions: Edentulous Jaw.
What interventions are being tested in trial NCT05062863?
The interventions under investigation include: T3 dental implant system (DEVICE).
Who is sponsoring clinical trial NCT05062863?
This trial is sponsored by ZimVie, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05062863 being conducted?
This trial has 4 study locations across Florida, New Jersey, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Edentulous Jaw
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI